Bruker’s Post

We are pleased to announce a collaborative agreement with the Universitat de Barcelona to develop and demonstrate new or enhanced applications of #NMR at 1 GHz for the pharmaceutical industry, especially in biologics and new drug modalities. The University of Barcelona installed in 2022 the first Avance Evo 1 GHz NMR instrument in Europe and is part of the Spanish Singular Scientific and Technical Large Scale Facilities network. The collaboration includes the synthesis of model therapeutic oligonucleotides by Dr. Terraza’s group at the University of Barcelona. Other therapeutics of interest are monoclonal antibodies, RNA, oligonucleotides, and peptides. This responds to the need to improve product risk assurance and the encouragement by the regulatory authorities to use state-of-the-art technology, including NMR. Read more: https://lnkd.in/dHYDJVD6 Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB) #CCiTUB #Bruker #Pharma #Biomedicine #NMRchat

Can mid-size molecules, particularly cyclic peptides, address challenges where antibodies and small molecules fall short? These molecules, which combine antibodies' targeting precision with small molecules' cell penetration, effectively engage intracellular "undruggable" targets. Cyclic peptides are especially promising because they penetrate cell membranes and interact with complex proteins inside cells. While the slides created by PeptiDream do not mention 中外製薬 / Chugai Pharmaceutical Co., Ltd., exploring Chugai's approach is intriguing. Their product, LUNA18, is already in clinical trials. Chugai Pharmaceutical leverages this potential through advanced technologies like mRNA display and proprietary synthesis methods, enhancing these peptides' drug-like properties and streamlining their development.  📄https://lnkd.in/gpChJwvY

Major Milestone: Clinical Candidate Selected in Project CT-03! We are excited to announce key progress in Captor Therapeutics' CT-03 project: ✅ Clinical candidate nominated after successful preclinical studies in Non-Human Primates 🧪 First-in-class cardiosafe MCL-1-targeting  molecule! 📅 IND/CTA filing planned for late 2025 "The drug candidate developed under the CT-03 project is "first-in-class" as, to the Company's knowledge, it is the only MCL-1 degrader currently in development by a pharmaceutical company. This approach,, as demonstrated in preclinical models in monkeys, shows a broad therapeutic window and subnanomolar to low nanomolar potency" said Dr. Michał Walczak, Chief Scientific Officer. Have a look at our white paper on MCL-1: https://lnkd.in/dnwuEnWP #biotech #drugdevelopment #clinicaltrials #cancerresearch #MCL1 #CaptorTherapeutics #innovation

Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics Successful development of advanced biotherapeutics relies on extensive characterisation and tight quality control. Characterising binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches have limited use in a complex biological environment with multiple interactions. To address these challenges, the speakers have developed and implemented better-performing and higher throughput technologies.   In this webinar, the speakers will discuss:  • Method of testing the interaction of a lead biosimilar antibody candidate versus a commercially available antibody • Develop an assay to determine the level of binding activity  • Utilisation of the assay in QC lot release Thu, May 2, 2024 3:00 PM - 4:00 PM BST This webinar is FREE to attend. Register now to secure your place! https://lnkd.in/eBqwy9GQ Supported by Revvity #Biotherapeutics #DrugDiscovery #LifeSciences

Two innovative NMR experiments have been developed to enhance the sensitivity and speed of biologic drug screening, facilitating the analysis and characterization of biologics during drug discovery. These methods allow for rapid assessment of structural stability and behavior, even at low concentrations. Their effectiveness is demonstrated through various examples, including therapeutic proteins and stressed samples. Learn more: https://lnkd.in/dVeBTBVf #NMR #Pharma #DrugScreening

Conventional ADME study methods in vitro 2D cell culture and in vivo animal models are limited by poor clinical translatability, which impacts the drug candidate selection process and dosage figures. In this American Pharmaceutical Review article, our Lead Scientist, Dr Yassen Abbas, talks about emerging complementary technologies, such as organ-on-a-chip (OOC), that allow for human-relevant in vitro preclinical studies. Additionally, he discusses how OOC technology can be applied to determine human bioavailability, inform dosing regimens, reduce side effects, and potentially recover flawed therapeutic candidates. Read the full article here: https://bit.ly/48OLe5U #OrganOnAChip #ADME #Bioavailability #Innovation

Fullerenes attracted a lot of interest since their discovery in 1985 because of their unique cage-like structure. Fullerene is an allotropic form of carbon and has interesting and unique chemical and physical properties, which can be used for the development of various therapeutic and biomedical applications. In the last few decades, fullerenes have been widely studied for the drug delivery of anticancer drugs and development of targeted drug delivery systems. In this chapter, we aim to cover the recent developments in anticancer drug delivery systems based on fullerenes. This chapter can be of interest to the pharmaceutical and biotechnology community to provide the most recent advances on fullerenes as targeted anticancer drug delivery systems with therapeutic applications and challenges.

What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies? Rajiv Nayar, President at HTD Biosystems and Chuck Sholtz, Vice President, Intellectual Property at Nutcracker Therapeutics explored current issues and strategies in this dynamic field from patent eligibility considerations for biologics and antibodies, strategies for prosecuting bispecific antibody patent applications around the world, and emerging trends in biologic and antibody patenting. Benjamin Pelletier, Partner at Haynes and Boone, LLP moderated the session. #LSPNFall #Patents #IntellectualProperty

Recently Rafał Derlacz – Technical Project Management Director at Polpharma Biologics – joined the group of experts delivering lectures as part of the Practical Biotechnology Course organized by the Medical Research Agency (Agencja Badań Medycznych)! The aim of the course is to educate and deepen participants' knowledge of biotechnology in a practical approach. During his presentation, Rafał discussed the development and registration of the first Polish biosimilar monoclonal antibody – natalizumab. His lecture covered topics such as: 🔬the mechanism of action of natalizumab  🧪the development history of the biosimilar natalizumab ⚙️optimization of the manufacturing process  💊development of the drug formulation  📝clinical trial strategy See you during future initiatives! #Biotechnology #ABM #PolpharmaBiologics #Natalizumab #BiotechEducation #Biosimilars